Icatibant Piramal

Icatibant, the active ingredient in Icatibant Piramal, is a bradykinin B2 receptor antagonist presented as an injectable solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema caused by C1‑inhibitor deficiency in affected patients.

GNH USA supplies Icatibant Piramal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for this injectable therapy. Customers benefit from consistent product availability and regulatory support across multiple regions.

Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema.

Acute hereditary angioedema (C1‑inhibitor deficiency): rapidly reduces edema and pain during attacks. Hereditary angioedema (Factor XII deficiency): provides symptom relief by blocking bradykinin effects. Bradykinin‑mediated angioedema: alleviates swelling when conventional therapies are ineffective. Hereditary angioedema (unknown etiology): offers effective control of acute swelling. Acute attacks not responding to C1‑inhibitor concentrate: serves as an alternative therapeutic option.

Icatibant may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain - Redness or swelling at injection site - Nausea - Headache

Serious or Rare Side Effects: - Severe hypersensitivity reactions including anaphylaxis - Laryngeal edema leading to airway obstruction - Significant hypotension

When using Icatibant, several precautions should be observed to ensure safe administration. - Renal impairment: adjust monitoring as drug clearance may be reduced. - Hepatic impairment: use with caution; limited data on safety. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown excretion; consider discontinuation if possible. - Concomitant ACE inhibitors or ARBs: may increase risk of angioedema; monitor closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines, affecting bradykinin levels or injection site reactions.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effect may precipitate angioedema. - Angiotensin receptor blockers (ARBs): similar risk of enhanced bradykinin‑mediated swelling.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of hypersensitivity. - Other subcutaneous biologics: increase local injection‑site irritation. - Warfarin or anticoagulants: monitor bleeding risk if severe hypotension occurs.